Related Experiment Video
Updated: Mar 11, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Conjunctival Melanoma Responsive to Combined Systemic BRAF/MEK Inhibitors
Lora R Dagi Glass1, Donald P Lawrence, Frederick A Jakobiec
1*Ophthalmic Plastic Surgery Service, Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School; †Cancer Center, Massachusetts General Hospital, Harvard Medical School; and ‡Department of Ophthalmology, David C. Cogan Laboratory of Ophthalmic Pathology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts, U.S.A.
Abstract:
This report demonstrates a unique case of conjunctival melanoma harboring a BRAF V600E mutation responsive to systemic therapy with BRAF and MEK inhibitors. While systemic therapy would not be appropriate in patients with local disease alone, it may act therapeutically in cases of higher stage ocular surface and eyelid melanoma.
More Related Videos
05:46Implantation and Evaluation of Melanoma in the Murine Choroid via Optical Coherence Tomography
Published on: December 2, 2022
06:46Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Published on: September 4, 2021
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Angle Closure Glaucoma: Treatment
Tumor Immunotherapy
Treatment Resistant Cancers
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...